Saratoga doctors face healthcare fraud, money laundering charges

Cara Livernois | | Health Exec | Management

A pair of doctors from California have been charged with committing healthcare fraud and money laundering, reports the Mercury News.

A federal grand jury have indicted doctors Vilasini Ganesh and Gregory Belcher with charges of healthcare fraud, conspiracy to commit healthcare fraud, money laundering and conspiracy to commit money laundering. Ganesh is also separately accused of submitting claims for services that she knew were not payable by including false codes that logged the seriousness of the patient's condition as well as the time the physician spent examining the patient, false diagnoses, false claims.

Ganesh, 46, a family practitioner and Belcher, 54, an orthopedic surgeon, have been accused of working a scheme between 2009 and 2014 to defraud insurance companies via the Campbell Medical Group, their medical practice, to illegally funnel money to themselves.

The total number of charges includes one count of healthcare fraud conspiracy, one count of conspiracy to commit money laundering and six counts of money laundering. Ganesh was also charged separately with five counts of healthcare fraud and five counts of false statements relating to healthcare matters.

They face 10 years in jail a fine of $250,000, plus restitution for the healthcare fraud conspiracy charges and 20 years in jail a fine of at least $500,000 for the money laundering charges.

""
Cara Livernois, News Writer

Cara joined TriMed Media in 2016 and is currently a Senior Writer for Clinical Innovation & Technology. Originating from Detroit, Michigan, she holds a Bachelors in Health Communications from Grand Valley State University.

Related Content

Q&A: Proposed changes to Social Security Act would recognize pharmacists as healthcare providers
FDA issues Class I recall on counterfeit infusion pump batteries
FDA issues alert on PCNL sheath safety after patient death
Bipartisan bills in Congress would force insurance companies, PBMs to sell pharmacies
Anthem BCBS reverses course on anesthesia time limits
FDA issues Class I recall on insulin syringes due to risk of death

Around the web

Cardiovascular Business
FDA says years-long tirzepatide shortage is resolved, will give limited leeway to compounders

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

AI in Healthcare
From Capitol Hill to a hospital near you? 5 federal recommendations for healthcare AI policy

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Cardiovascular Business
Merck spends up to $2B to license new weight loss drug with potential heart benefits

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.